These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35245876)

  • 21. Clinical relevance of serum ionized magnesium concentration in dogs with myxomatous mitral valve disease.
    Kim OK; Kim K; Park S; Yang H; Kim H; Ro WB; Lee CM
    J Vet Intern Med; 2024; 38(1):41-50. PubMed ID: 38064361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Newhard DK; Jung S; Winter RL; Duran SH
    J Vet Intern Med; 2018 Sep; 32(5):1555-1563. PubMed ID: 30084228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
    Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
    J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK; DeFrancesco TC; Meurs KM; Papich MG
    J Vet Intern Med; 2023; 37(6):2003-2010. PubMed ID: 37776546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
    Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
    PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G; Kresken JG; Wendt R; Gaugele J; Killich M; Keller L; Simak J; Holler P; Bauer A; Küchenhof H; Glaus T
    J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
    Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
    Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Echocardiographic evaluation of deformity and enlargement of the canine mitral valve annulus associated with myxomatous degenerative mitral valve disease.
    Mihara K; Kanemoto I; Sato K; Yasuhira Y; Watanabe I; Misumi K
    J Vet Cardiol; 2021 Oct; 37():8-17. PubMed ID: 34507141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severity of myxomatous mitral valve disease in dogs may be predicted using neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratio.
    Ku D; Chae Y; Kim C; Koo Y; Lee D; Yun T; Chang D; Kang BT; Yang MP; Kim H
    Am J Vet Res; 2023 Jun; 84(6):. PubMed ID: 37024099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
    BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Müller S; Menciotti G; Borgarelli M
    J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of concurrent lower respiratory tract disease on point-of-care lung ultrasound in small-breed dogs with myxomatous mitral valve disease.
    Lam MC; Lin CH; Lo PY; Wu HD
    J Vet Intern Med; 2022 May; 36(3):1075-1081. PubMed ID: 35475522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ; Boswood A; López-Alvarez J; Lötter N; Elliott J
    J Vet Cardiol; 2017 Aug; 19(4):325-338. PubMed ID: 28734620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
    J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tricuspid annular plane systolic excursion in dogs with myxomatous mitral valve disease with and without pulmonary hypertension.
    Poser H; Berlanda M; Monacolli M; Contiero B; Coltro A; Guglielmini C
    J Vet Cardiol; 2017 Jun; 19(3):228-239. PubMed ID: 28579307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Longitudinal Outcome Of Canine (K9) myxomatous mitral valve disease (LOOK-Mitral registry): Baseline characteristics.
    Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
    J Vet Cardiol; 2021 Aug; 36():32-47. PubMed ID: 34062479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study.
    Chetboul V; Pouchelon JL; Menard J; Blanc J; Desquilbet L; Petit A; Rougier S; Lucats L; Woehrle F;
    J Vet Intern Med; 2017 Nov; 31(6):1629-1642. PubMed ID: 28975664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease.
    Li Q; Freeman LM; Rush JE; Laflamme DP
    Int J Mol Sci; 2015 Jun; 16(6):14098-108. PubMed ID: 26101868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction and measurement of diuretic responsiveness after oral administration of furosemide to healthy dogs and dogs with congestive heart failure.
    Loughran KA; Larouche-Lebel É; Huh T; Testani JM; Rao VS; Oyama MA
    J Vet Intern Med; 2020 Nov; 34(6):2253-2264. PubMed ID: 33125814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease.
    Iwasa N; Kumazawa R; Nomura S; Shimizu M; Iwata M; Hara M; Kawabe M; Kobatake Y; Takashima S; Nishii N
    J Vet Intern Med; 2023 Mar; 37(2):412-419. PubMed ID: 36852471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.